Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study

[Display omitted] •Real-world SURE programme data complement those from the SUSTAIN clinical trials.•SURE Denmark/Sweden studied local use of once-weekly semaglutide in adults with T2D.•Semaglutide was associated with significant HbA1c and body weight reductions.•No new safety concerns were reported.•These data support the clinical use of once-weekly semaglutide in Denmark/Sweden. As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden. SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA1c value ≤12 weeks before initiating semaglutide at their physician’s discretion. Primary (change in HbA1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS). Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA1c and body weight between baseline and EOS were –1.2 [–1.3; –1.1]%-points (–13 [–14; –12] mmol/mol) and –5.4 [–6.0; –4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA1c